Introduction
Cancer immunotherapy has been associated with augmentation of immune response via in vivo vaccination or ex vivo expansion of antigen specific effector cells that show cytotoxicity and secretion of inflammatory molecules. Preclinical studies have demonstrated the important role of APC in antigen presentation to prime T lymphocytes. For effective induction of T cell mediated immune response, efficient presentation of antigen peptides is required. Among the various APCs including dendritic cells (DC) (Metlay et al., 1989; Romani et al., 1989; Steinman et al., 1993; Salusto et al., 1994; Celluzzi et al., 1996; Paglia et al., 1996) , activated macrophages (Rock et al., 1993) or activated B cells (Gollob et al., 1993; Liu et al., 1994; Topalian et al., 1994; Constant et al., 1995; Mitchell et al., 1995; Schultze et al., 1995; Ke et al., 1996; Vidard et al., 1996) , lymphoblastoid B cell lines (LCL) (Livingston et al., 1997; Barbara et al., 2002) , the best known APC is DC for its potency in antigen capture, processing and migration (Steinman et al., 1993) .
Most of studies on generation of antigen specific T cells in vitro have used dendritic cells for its capacity; antigen capture and efficient presentation. Antigenloaded DC has been clinically tested in phase II and III trials for the treatment of cancer including melanoma, prostate cancer, B cell lymphoma, cutaneous T cell lymphoma and metastatic renal cell carcinoma (Hsu et al., 1998; Thurner et al., 1999; Kugler et al., 2000; Banchereau et al., 2001; Heiser et al., 2002; Rini et al., 2002; Meier et al., 2003) . However, in order to prime naive T cells to be antigen specific, the fact that DCs only constitute 0.1-0.5% of human PBMC has hampered generating a large numbers of matured DC (Girolomoni et al., 1997) . To overcome the small portion of DCs in PBMC, monocytederived DCs have been most widely used as they can be simply generated using plastic adherent method with GM-CSF and IL-4 (Bender et al., 1996) . DCs generated via this method are not fully functional in stimulating antigen-specific T cells in vitro or migrating into the regional lymph nodes in vivo. Various stimuli such as inflammatory cytokines are required for complete maturation of immature DCs. Recently, cellular immunotherapy for clinical application requires more number of alternative APCs as potent as DCs that can be generated in a short time and can be expanded continuously. CD40L, mainly expressed on activated CD4 + T lymphocytes, has been one of the most commonly used inducing molecule of B cell activation. It causes upregulation of activation signal to B cells, costimulatory molecules such as CD80, CD83, CD86 and MHC Class I and II at level comparable to DCs (joachim et al., 1997) . Studies on B cell activation via CD40-CD40L interaction have been performed with various types of CD40L including soluble form (sCD40L), monoclonal antibody or cellular mediated expression. In any cases, CD40-CD40 ligand interaction caused B cell proliferation. The activated B cells demonstrated its capacity as functional APC by generating Ag-specific cytotoxic T lymphocytes (CTL) in vitro (Eisei et al., 2002; Michael et al., 2002) .
In the current study, we developed non-allogenic and non-xenogenic B cell stimulating system by establishing a cell line derived from Drosophila melanogaster, Schneider 2 (S2) cells stably expressing CD40 ligand (S2-CD40L). Here we observed that the use of S2-CD40L allows rapid activation of B cells and CD40-activated B cells fulfill the criteria of optimal APC.
Materials and Methods

Donors and cell lines
Leukocytes obtained from healthy donors, HLA-A*0224 + and HLA-A*0201 + by leukapheresis were separated by density centrifugation through Ficoll (Pharmacia, Piscataway, NJ) to yield PBMC. Isolated peripheral blood monocytes were then washed with PBS, resuspended in Iscove's modified Dulbecco's medium (IMDM) (Cambrex, Walkersville, MD) medium containing 10% FBS (Cambrex). Activation of B cell B cells were purified by means of the MiniMACS separation method (Miltenyi Biotech, Bergisch Gladbach, Germany) using cocktail of biotin-conjugated monoclonal antibodies against CD2, CD14, CD16, CD36, CD43 and CD235a (Glycophorin A). The fraction of B cells in the starting sample was determined by flow cytometry 90%. The purified B cells were resuspended at a concentration of 5 × 10 5 /ml in IMDM medium containing 10% FBS and were plated on 12-well plates. B cell suspension was cocultured with anti-CD40 mAb (10 µg/ml) or S2-CD40L cells with at various ratio in the presence of 4 ng/ml IL-4 (Endogen, Woburn, MA), 5 µg/ml insulin (Sigma), 50 µg/ml transferrin (Boehringer Mannheim, Indianapolis, IN) at 37 o C in 5% CO 2 . Cultured cells were transferred to new plates with fresh S2-CD40L cells or anti-CD40 mAb on day 3. Before the addition of S2-CD40L, dead cells and debris were removed from Ficoll density centrifugation. At day 6, activated B cells were Ficoll-density centrifuged followed by washing with PBS twice to remove nonviable cells including remaining S2-CD40L cells.
Constructs
Flow cytometry
Phenotypes of CD40 activated B cell populations and CD40L on S2 cells were analyzed by flow cytometry using a FACScan flow microfluorometer (BD Biosciences, Mountain View, CA) as previously described (Kim et al., 2004) . Fluorescence profiles were generated by analyzing 10,000 cells and displayed as histogram vs. cell numbers. Activated B cells were analyzed for PE-conjugated CD86 and FITC-conjugated HLA Class II and S2-CD40L for PE-conjugated CD154. Apoptic cells were analyzed for PE-conjugated AnnexinV. All fluorescence-conjugated Abs were purchased from BD Pharmingen. In brief, 1 million viable B cells in 100 µl of PBS were rinsed twice with PBS containing 2% FBS. The cells were then stained for 20 min with 0.5 µg of the following appropriate mAbs. The stained cells were washed and fixed with 1% paraformaldehyde in PBS. FACS analysis was performed using the abovementioned FACScan flow cytometer and CellQuest software (BD Biosciences).
Mixed lymphocyte reactions (MLR)
MLR is performed for measuring viable T cell using XTT assay as previously described (Lee et al., 2005) . Briefly, whole CD3 + T cells or T cell subsets from healthy individuals were plated at 1 × 10 5 T cells/well with 10 5 irradiated (32 Gy) CD40 activated B cells or B cells/well in 100 µl RPMI-1640 supplemented with 10% FBS (Cambrex), 2 mM glutamine (Gibco/BRL, Gaithersburg, MD) in 96-well plates for up to 6 days. On day 6, viable cells were labeled with 50 µl of 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT) reagents (Cell Proliferation kit II) according to the manufacturer's protocol (Boehringer Mannheim) as a measure of cell proliferation. Absorbance was measured with a Thermo max microplate reader at 490 nm and reference wavelength of 650 nm.
Enzyme-linked immunospot (ELISPOT) assays
ELISPOT assays were performed as described earlier . In brief, a commercially available ELISPOT kit was used (AID, Jessup, MD). B cells activated for 6 days by S2-CD40L and loaded with pp65 peptide (10 µg/ml) (NLVPMVATV) were used as stimulator cells. The CD14 + cells depleted peripheral blood lymphocytes (PBLs) (1 × 10 5 cells/ well) were mixed with activated B cells (1 × 10
Statistical analysis
Data are expressed as means ± SD. Differences were considered statistically significant for P values using a Student's t-test compared to other groups.
Results
Stable S2 transfectant expressing CD40L
S2 cells was co-transfected with the CD40L expression plasmid containing constitutive Ac5 promoter and selection vector plasmid encoding hygromycin resistant gene (Figure 1) . The transfectants were selected with hygromycin-B and tested for its expression using PE-conjugated CD40L ( 90%) by flow cytometry. Its expression was stable for a year and often analyzed by flow cytometry.
To verify whether CD40L expression can be maintained at which B cells are cultured, 37 o C, S2-CD40L transfectants were suspended in B cell media, IMDM (10% FBS) and incubated at 37 o C. A fraction of cultured S2-CD40L cells was daily analyzed for its CD40L expression by flow cytometry and Figure 2A shows the expression maintained up to at least 3 days even at 37 o C. When S2-CD40L transfectants were cultured at 37 o C, we hourly observed membrane instability through microscopic analysis and found out the degree of instability increased as the culture period extends (data not shown). Therefore we tested to define whether incubation at different temperature leads S2-CD40L to either necrosis or apoptosis using apoptosis kit by staining with 7AAD for necrosis and annexinV for apoptosis. As the incubation time increases, the number of cells stained for annexinV increased from day 0, 1, 2 to 3; 2%, 32%, 48%, and 68% respectively ( Figure 2B ). The first day of culture at 37 o C leads the number of population stained for apoptosis from 2% to 30% and two more days of culture increased more than two folds.
B cell activation by coculturing with S2-CD40L
To investigate whether S2-CD40L/B ratio is critical in activating B cells, we incubated different numbers of S2-CD40L with a fixed number of B cells at the ratios from 1:16 to 1:1. Although the activated cells seemed "clumped" at every ratio, Figure 3A shows the maximal increase of total B cells at the ratio of B cells to S2-CD40L, 2:1. Although B cells were tested at the ratio of 1:1, the increase of B cells was similar to the ratio of 2:1. Figure 3B showed that S2-CD40L stimulated B cells more efficiently than anti-CD40 mAb in B cell proliferation for 6 days (P 0.01). B cells incubated alone or cultured with S2 cells (S2-B) did not increase in cell number and eventually died after all.
To examine the phenotypic change on B cells, a fraction of B cells on day 0, 3 and 6 was tested for the expression of costimulatory CD86 and MHC Class II molecules. These cells were highly activated as shown by the increase of activation marker in Figure 4 . The expression of CD86 and MHC Class II by day 6 was highly increased compared to that by day 0 and 3 (P 0.01). On day 3, the expression of CD86 and Class II did not increase significantly and remained similar levels as in day 0. However after the second stimulation of B cells with S2-CD40L on day 3 and further incubation, the expression of activation marker increased significantly (P 0.01). In comparison, B cells stimulated with control S2 cells did not show significant phenotypic changes (P 0.05). We also examined the expression of activated B cells cultured more than 6 days and expression of these molecules along with B cells lineage marker remained stable thereafter (data not shown).
Efficient stimulation of T cells by B cells activated with S2-CD40L
To assess APC capacity of activated B cells cultured with S2-CD40L or anti-CD40 mAb, B cells were harvested at day 6 and used as stimulators for CD4 + T cells. In MLR of Figure 5A , B cells activated with S2-CD40L could significantly increase T cell proliferation (P 0.01) compared to those of B cells incubated alone or B cells cultured with S2 cells (S2-B) . Furthermore, B cells activated with anti-CD40 mAb were not as efficient as B cells activated with S2-CD40L (P = 0.01). To also evaluate the capacity of antigen presenting capacity of B cells activated with S2-CD40L, we pulsed the B cells with the immunogenic HLA-A*0201 binding peptide from pp65, HCMV associated antigen, and subsequently stimulated PBLs. As shown in ELISPOT assay of Figure 5B , CD40 activated B cells pulsed with peptide induced IFN-γ secreting T cells (50 ± 1.04) in 10 5 PBLs (P 0.01). In contrast, no or a few IFN-γ spots were formed against PBLs only, PBLs with unpulsed B cells or PBLs with S2-B cells, 
Discussion
Previous studies on B cell activation have been done with various types of CD40L. Mainly the two forms including soluble CD40L and membrane bound CD40L could be used. Michael et al., (2002) showed that GMP-grade soluble trimeric CD40L can be used to activate B cells and demonstrated its capacity to generate antigen specific T cells in vitro.
Although maintaining constitutive expression of CD40L of membrane-bound form is laborious and operating with soluble CD40L is convenient, soluble CD40L is known to have a lower stimulating potential than membrane-bound form. Among the membrane-bound form of CD40L, NIH3T3 expressing CD40L, was mostly used to activate B cells. Recently 293T cells were also manipulated to express CD40L and demonstrated the complete activation and significant proliferation of B cells (Ivanov et al., 2005) . However using mammalian expression to activate B cells provides concerns such as allogenic response for 293T and xenogenic response for NIH3T3 cells. To avoid those issues, Wendy et al., (1995) established Spodopzeru frugiperda cell line, SF9, to express CD40L and stimulated B cells to activate. However CD40L on SF9 cells is expressed in a baculovirus system, thus safety concerns for viral product from infected SF9 cells cannot be ignored. In contrast to previous studies on activating B cells (Joachim et al., 1995; G.A. et al., 2005) , we used insect embryo cell line, S2 that has been used as artificial APC (AAPC). Mammalian cells used as AAPC provided concerns for nonspecific stimulation of CD8 + and reactivity of natural killer cells (Janetzki et al., 2000) . However, the fact that insect cells do not process or present antigens through MHC class pathway due to the lack of endogenous machinery lowered reactivity against insect cells by effector cells. In addition, mammalian cell lines used as AAPC need to be irradiated in order to stimulate T cells, however S2 cells are conveniently self-eliminated at 37 o C, thus irradiation step is unnecessary when cultured, in this case for activating B cells.
Current study has utilized CD40-CD40L interaction of B cell to activate and mature to become a potent APC. By genetical manipulation of S2 cells, we established a cell line constitutively expressing CD40L, a molecule mostly used to activate B cells. From the incubation of S2-CD40L and B cells only for 6 days, we observed proliferation, changes in morphology and maturation marker, CD86 and MHC Class II on B cells. MLR using B cells activated with S2-CD40L as APC showed that activated B cells could induce T cell proliferations and demonstrated Van et al., 2001; Posaerts et al., 2003) . In addition to CD40 activated B cells, B cells immortalized using EBV lymphoblastic cell line (EBV-LCL) efficiently expanded Ag-specific T cells (CD4 + and CD8 + ) and demonstrated its capacity as APC (Sun et al., 1987; Okamura et al., 2003) . Although generation of EBV-LCL is simple and can be expanded while maintaining its APC function, the safety concern of using live virus to generate LCL still remains and it requires about 4-6 weeks to be established. Currently, our lab seeks to generate "APC cocktail" including LCL, DC and CD40 activated B cells to efficiently stimulate T cells in vitro. The use of APC combination including LCL, DC and CD40 activated B cells may overcome the limitation of use of single APC. Each APC would function its potent role in different mechanism and the use of APC cocktail will generate more efficient and natural form of cytotoxic T lymphocytes. In this study, we suggest that activated B cells can be easily and conveniently generated using insect cell line, S2-CD40L and the results of this study may impact on the development of B cell-based anticancer immunotherapy.
